Air pollution slashes the survival chances for heart transplant patients, finds study
Researchers from Case Western Reserve University in Ohio found those who lived in areas with high pollution levels were 26 per cent more likely to die within 4.8 years of the operation.
Jacobs took over just as the heart transplant program was imploding. The program is now on the mend.
We report one case of a recent renal transplant recipient, who presented with gastrointestinal and respiratory symptoms, evolving into shock. The identification of Strongyloides stercoralis in the bronchoalveolar lavage (BAL) lead us to the diagnosis of SHS. Treatment with subcutaneous ivermectin was started, however the patient did not survive. Retrospective serum donor analysis allowed us to identify the donor as the source of infection.
CONCLUSION: A VAD system can be implanted as an alternative to cardiac transplan- tation or as a bridging treatment until the patient can be listed for transplantation and receive the transplant. Because of the organ s , only a minority of VAD patients ever receive a transplant. PMID: 31931951 [PubMed - in process]
We present a case report of a heart failure patient after heart transplantation due to end-stage ischemic cardiomyopathy with significant clinical and echocardiographic improvement 3 months after the introduction of sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor. This new class of drugs is proved to be beneficial in heart failure patients, especially with reduced ejection fraction (HFrEF), but they have not yet been used in heart failure patients after heart transplantation. We believe that the increase of left ventricular systolic function, improvement of global longitudinal strain, and reduction of pu...
WEDNESDAY, Jan. 15, 2020 -- For patients with advanced heart failure, the HeartMate 3 (HM3) left ventricular assist device (LVAD) is superior to the HeartMate II (HMII), regardless of whether the device is a bridge to transplant (BTT) or a...
(Washington University School of Medicine) A new study from Washington University School of Medicine in St. Louis suggests that extremely rare, harmful genetic mutations present in healthy donors' stem cells -- though not causing health problems in the donors -- may be passed on to cancer patients receiving stem cell transplants, potentially creating health problems for the recipients. Among the concerns are heart damage, graft-versus-host disease and possible new leukemias.
THE UNITED Network for Organ Sharing (UNOS) adopted the label “high risk” from the Public Health Service (PHS) in 2004 in order to improve organ safety by reducing disease transmission. This has resulted in nonutilization of organs from patients who are otherwise healthy but deemed high risk because of social behaviors or illicit drug use. Organ availabili ty remains the limiting factor to organ transplantation, and the number of patients awaiting transplantation is outpacing the number of transplantations being performed.
We examined the correlates of R-V/A and traditional echocardiographic indices of RVSD, over the spectrum of pulmonary hypertension and tertiles of mean pulmonary artery pressures (PAPm). Methods In 2016–2017, we studied 81 consecutive patients for heart transplant/advanced heart failure. Inclusion criteria were NIDCM, reduced ejection fraction (≤40%) and sinus rhythm. R-V/A was computed as the RV/pulmonary elastances ratio (R-Elv/P-Ea), derived from a combined right heart catheterization/transthoracic- echocardiographic assessment [right heart catheterization/transthoracic-echocardiographic (RHC/TTE)]. Results...
Title: Heart Transplants From Donors With Hepatitis C May Be Safe: StudyCategory: Health NewsCreated: 1/13/2020 12:00:00 AMLast Editorial Review: 1/14/2020 12:00:00 AM
An adult patient received a “donation after circulatory death” (DCD) heart transplant in the first such procedure to take place in the United States. Surgeons at Duke University Hospital in Durham, North Carolina, recently performed the operation as part of a clinical trial evaluating the Organ Care System (OCS) Heart, an investigational normothermic preservation system from Massachusetts-based TransMedics. An alternative to cold storage, the device keeps the donor heart pumping with warm oxygen- and nutrient-rich blood.